In the TROG 01.04 trial, patients with T3 adenocarcinoma of the rectum were rand omized to receive either preoperative SC radiotherapy 5 Gy x 5 or preoperative LC chemoradiotherapy 1.8 Gy x 28 concurrent with continuous infusion 5-FU. Both arms receive adjuvant chemotherapy postsurgery. What differences in acute adverse events were seen?